Max Robotics — Global Service Robot Directory + US Certification

About

Scott Williams is a leading urological surgeon and researcher whose work has fundamentally shaped the evidence base for surgical treatment of localised prostate cancer. His primary research areas centre on the comparative effectiveness of robotic-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy, and the integration of novel radioligand therapies into the surgical pathway. Williams’s landmark contributions include leading the first randomised controlled phase 3 study to compare robotic and open prostatectomy, published in *The Lancet* in 2016, which demonstrated that robotic surgery reduces hospital stay and perioperative morbidity. This seminal work, along with its 24-month follow-up, has garnered over 1,150 combined citations, establishing a new standard for surgical decision-making. More recently, Williams has pioneered the use of [177Lu]Lu-PSMA-617 prior to radical prostatectomy in high-risk localised disease through the LuTectomy trial, a phase 1/2 study that opens a promising frontier in neoadjuvant theranostics. His sustained commitment to rigorous randomised trial methodology, from early feasibility studies to large-scale outcome analyses, has provided the urological community with high-quality evidence to guide treatment choices and improve patient outcomes.